BH3 Mimetics Explained: Drugging the BCL-2 Family

The Mechanism

Anti-apoptotic proteins survive by clamping their hydrophobic groove around the BH3 helix of pro-death partners. A BH3 mimetic inserts into that groove, competitively displacing the bound partner.

The freed activator proteins, such as BIM, are then available to switch on BAX and BAK. In a cell that is already primed for death, this displacement is enough to trigger apoptosis within hours.

Venetoclax: BCL2-Selective

Venetoclax binds BCL2 with high selectivity, sparing BCL-XL and therefore avoiding the on-target thrombocytopenia that limited earlier dual BCL2/BCL-XL inhibitors like navitoclax.

It is approved in chronic lymphocytic leukaemia, often with an anti-CD20 antibody, and in acute myeloid leukaemia combined with a hypomethylating agent for patients not suited to intensive chemotherapy. Tumour lysis syndrome risk requires a careful dose ramp-up.

Why MCL1 and BCL-XL Are Harder

Many solid tumours and some leukaemias depend on MCL1 rather than BCL2. MCL1 inhibitors have shown activity in the laboratory but carry a risk of cardiac toxicity because heart muscle relies on MCL1, and clinical development has been cautious.

BCL-XL inhibition causes dose-limiting thrombocytopenia because platelets depend on BCL-XL for their lifespan. Degrader and platelet-sparing strategies are being tested.

Predicting Response with BH3 Profiling

BH3 profiling exposes permeabilised cells to synthetic BH3 peptides and measures how readily mitochondria release cytochrome c. It estimates how primed a cell is and which guardian it depends on.

This assay is mainly a research and trial tool, but it captures the underlying logic: a mimetic only helps if the cell is already loaded with death signals and relies on the targeted protein.

Resistance Mechanisms

Tumours escape BH3 mimetics by upregulating a different guardian (commonly MCL1 when BCL2 is blocked), by acquiring BAX mutations, by reducing activator BH3-only proteins, and by clearing damaged mitochondria through mitophagy before permeabilisation completes.

Combination strategies aim to cover more than one guardian or to pair a mimetic with agents that raise pro-apoptotic signalling.

Key Takeaways

• ·BH3 mimetics competitively displace pro-apoptotic proteins from anti-apoptotic ones.
• ·Venetoclax is BCL2-selective and established in CLL and AML.
• ·MCL1 and BCL-XL inhibition are limited by cardiac and platelet toxicity respectively.
• ·Resistance often involves a switch to a different guardian protein.